P S Haber
Overview
Explore the profile of P S Haber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ling R, White B, Roberts J, Cretikos M, Howard M, Haber P, et al.
BMC Health Serv Res
. 2022 Nov;
22(1):1326.
PMID: 36348369
Background: In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to...
2.
Freyer C, Morley K, Haber P
Intern Med J
. 2016 Nov;
46(11):1259-1268.
PMID: 27813358
Alcohol use disorders are common in Australia and are often unrecognised. Alcohol places a significant burden on our healthcare system by increasing the risk of injuries as well as many...
3.
Apte M, Haber P, Norton I, Wilson J
Addict Biol
. 2016 Jan;
3(2):137-50.
PMID: 26734819
Alcoholic pancreatitis is a major, often lethal complication of alcohol abuse. Until recently it was generally accepted that alcoholic pancreatitis was a chronic disease from the outset. However, there is...
4.
Morley K, Baillie A, Leung S, Sannibale C, Teesson M, Haber P
Alcohol Alcohol
. 2015 Dec;
51(4):402-9.
PMID: 26672793
Aim: To assess the effectiveness of a 12 week specialized, integrated intervention for alcohol dependence with comorbid anxiety and/or mood disorder using a randomized design in an outpatient hospital setting....
5.
Alavi M, Micallef M, Fortier E, Dunlop A, Balcomb A, Day C, et al.
J Viral Hepat
. 2015 May;
22(11):914-25.
PMID: 25996567
Among people who inject drugs (PWID) with chronic HCV, the association between HCV treatment willingness and intent, and HCV specialist assessment and treatment were evaluated. The Enhancing Treatment for Hepatitis...
6.
Duly A, Alani B, Huang E, Yee C, Haber P, McLennan S, et al.
Nutr Diabetes
. 2015 Apr;
5:e154.
PMID: 25915743
Background: Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are highly prevalent liver diseases that may coexist and contribute significantly to liver disease-related mortality. Obesity is a common...
7.
Morley K, Baillie A, Leung S, Addolorato G, Leggio L, Haber P
Alcohol Alcohol
. 2014 Sep;
49(6):654-60.
PMID: 25246489
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. Methods: Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to...
8.
Islam M, Conigrave K, Day C, Nguyen Y, Haber P
Intern Med J
. 2014 Jan;
44(1):57-64.
PMID: 24450521
Aim: Considerable concern has been expressed about overprescribing of benzodiazepines and related harms. Past analyses have relied on World Health Organization-defined daily doses (DDD) which are sometimes out of keeping...
9.
Morley K, Leung S, Baillie A, Haber P
Contemp Clin Trials
. 2013 Aug;
36(2):348-55.
PMID: 23939511
Background: Effective treatments for alcohol use disorders in those with significant liver disease are critically lacking. The primary aim of the current study is to explore the effectiveness and biobehavioural...
10.
Leong M, Murnion B, Haber P
Intern Med J
. 2009 May;
39(10):676-81.
PMID: 19460051
Background: Opioid prescribing is controversial with evidence of both significant under-utilization and over-utilization. There is some evidence to support efficacy for chronic non-malignant pain, but community and individual harms are...